Background And Aims: The incidence of inflammatory bowel disease [IBD] is stabilising in many Western countries. Some still show increasing incidence. Our objective was to determine the latest trends in IBD incidence and prevalence in Finland and to compare these among different age groups and between different geographical areas.
Methods: We used the nationwide registry of the Social Insurance Institute of Finland to identify new IBD cases during the period 2000-2020. Crude, age-specific, and age-standardised incidence rates were calculated. Prevalence was estimated using valid reimbursements from the same database in 2000-2020.
Results: We identified 42 498 new IBD cases. The crude annual incidence increased in ulcerative colitis [UC] from 20 to 35 (incidence date ratio [IRR] 1.03, 95% confidence interval [CI] 1.02-1.03), in Crohn's disease [CD] from 8 to 13 [IRR 1.02, CI 1.02-1.03] and in IBD overall from 28 to 48 per 100 000 person-years [IRR 1.02, CI 1.02-1.03]. Men had higher incidence than women in UC, but in CD the incidences were equal. The incidence of IBD increased in all age groups except for small children. The increase in both UC and CD was most marked among the elderly aged over 70. A north-south gradient was discernible. The crude prevalence of IBD increased from 376 to 972 per 100 000 (prevalence rate ratio [PRR] 1.05, CI 1.05-1.05).
Conclusions: The incidence of IBD, UC, and CD is increasing in Finland. The increase is most notable in the elderly. Current prevalence of IBD is 1%.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1093/ecco-jcc/jjac177 | DOI Listing |
JMIR Public Health Surveill
January 2025
School of Public Health, National Defense Medical Center, Taipei City, Taiwan.
Background: Japanese encephalitis (JE) is a zoonotic parasitic disease caused by the Japanese encephalitis virus (JEV), and may cause fever, nausea, headache, or meningitis. It is currently unclear whether the epidemiological characteristics of the JEV have been affected by the extreme climatic conditions that have been observed in recent years.
Objective: This study aimed to examine the epidemiological characteristics, trends, and potential risk factors of JE in Taiwan from 2008 to 2020.
JMIR Med Inform
January 2025
Department of Endocrinology and Metabolism, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China.
Background: Many tools have been developed to predict the risk of diabetes in a population without diabetes; however, these tools have shortcomings that include the omission of race, inclusion of variables that are not readily available to patients, and low sensitivity or specificity.
Objective: We aimed to develop and validate an easy, systematic index for predicting diabetes risk in the Asian population.
Methods: We collected the data from the NAGALA (NAfld [nonalcoholic fatty liver disease] in the Gifu Area, Longitudinal Analysis) database.
J Oncol Pharm Pract
January 2025
Department of Pharmacy, Shaukat Khanum Memorial Cancer Hospital and Research Centre, Lahore, Pakistan.
Study Objective: Complex pharmacotherapy in cancer patients increases the likelihood of drug-drug interactions (DDIs). Pharmacists play a critical role in the identification and management of DDIs. The aim of present study was to evaluate the role of pharmacist in identifying antifungal drug interactions in cancer patients and providing relevant recommendations.
View Article and Find Full Text PDFConfl Health
January 2025
London School of Hygiene and Tropical Medicine, Department of Non-Communicable Diseases Epidemiology, Keppel street, London, WC1E 7HT, UK.
Background: Non-communicable diseases (NCDs) are the leading cause of death globally, and many humanitarian crises occur in countries with high NCD burdens. Peer support is a promising approach to improve NCD care in these settings. However, evidence on peer support for people living with NCDs in humanitarian settings is limited.
View Article and Find Full Text PDFNeurol Res Pract
January 2025
Institute of Clinical Epidemiology and Biometry, Julius-Maximilians-Universität Würzburg (JMU), Haus D7, Josef-Schneider-Straße 2, 97080, Würzburg, Germany.
Background: Comprehensive clinical data regarding factors influencing the individual disease course of patients with movement disorders treated with deep brain stimulation might help to better understand disease progression and to develop individualized treatment approaches.
Methods: The clinical core data set was developed by a multidisciplinary working group within the German transregional collaborative research network ReTune. The development followed standardized methodology comprising review of available evidence, a consensus process and performance of the first phase of the study.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!